VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BMGLBasel Medical Group Ltd Ordinary Shares
$6.87$11M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBMGLCash Flow

Basel Medical Group Ltd Ordinary Shares (BMGL) Cash Flow Statement

4Y historyFree accessUpdated daily

Operating cash flow of -$302.7K against $5.4M in claims paid indicates that the company is failing to generate sufficient float to support its core medical service delivery.

BMGL Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricJun'25Jun'24Jun'23Jun'22
Cash from Operations-4.34M2.51M2.6M2.79M
Operating CF Growth %-273.12%-3.49%-6.89%-
Operating CF / Revenue %-38.38%24.97%26.8%26.2%
Net Income-12.51M2.4M2.13M2.39M
Depreciation & Amortization1.18M528.73K557.13K575.92K
Stock-Based Compensation0000
Deferred Taxes0000
Other Non-Cash Items10.23M-419.19K-375.51K-251.26K
Working Capital Changes-3.25M-4.82K286.8K81.37K
Cash from Investing-11.04M-7.92K-6.16K-88.5K
Capital Expenditures-54.76K-7.92K-6.16K-88.5K
Acquisitions-10.99M000
Purchase of Investments0000
Sale/Maturity of Investments0000
Other Investing0000
Cash from Financing16.91M-1.77M-2.94M-12.92M
Dividends Paid0000
Share Repurchases0000
Stock Issued9.75M000
Debt Issuance (Net)-1000K-1000K-1000K-1000K
Other Financing12.34M1.16M325-10.86M
Net Change in Cash1.03M733.61K-346.24K-10.22M
Exchange Rate Effect-495.74K000
Cash at Beginning1.95M1.22M1.56M11.78M
Cash at End2.98M1.95M1.22M1.56M
Free Cash Flow-4.4M2.5M2.59M2.7M
FCF Growth %-275.86%-3.56%-4.07%-
FCF Margin %-38.86%24.89%26.74%25.37%
FCF per Share-2.811.851.922

Key Metrics

Growth RegimeExpanding
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Unsustainable Cash Burn Rate

Negative Float Impairs Cash Generation

As reported in the 2024Q4 financial statements, BMGL generated an operating cash flow of -$302.7K against $5.4M in claims paid, indicating that the company is currently unable to leverage premium float to offset its operational expenses or fund its ongoing medical service delivery requirements.

The negative operating cash flow suggests that the company is effectively subsidizing its claims payments with external capital rather than internal premium generation. This dynamic implies that the current underwriting model is not yet self-sustaining, as the cash outflow for claims exceeds the net cash inflow from premiums.

Statutory Earnings Divergence From Reality

Based on the 2024Q4 data, the company reported a net loss of $9.9M while maintaining a cash burn of $302.7K, which suggests that significant non-cash accruals or accounting adjustments are masking the true severity of the company's underlying cash-based operational deficit.

The wide gap between the net loss and the operating cash flow warrants further investigation into the nature of these accruals, as they may represent non-cash charges that do not reflect the actual liquidity pressure. Investors should monitor whether these adjustments are temporary accounting artifacts or indicative of structural issues in revenue recognition.

Liquidity Constraints Obscure Operational Risks

According to the latest quarterly figures, the company's cash position of $2.9M appears insufficient to cover the current burn rate, suggesting that BMGL may face significant liquidity risks if it cannot rapidly achieve operating leverage or secure additional financing to support its ongoing expansion.

The reliance on external funding to bridge the gap between claims payments and premium receipts indicates a vulnerable balance sheet position. This situation implies that the company's ability to continue its current growth trajectory is highly dependent on capital market conditions rather than internal cash generation.

BMGL — Frequently Asked Questions

Quick answers to the most common questions about buying BMGL stock.

How much cash does Basel Medical Group Ltd Ordinary Shares (BMGL) generate from operations?

Basel Medical Group Ltd Ordinary Shares (BMGL) generated $-4.3M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.

What is Basel Medical Group Ltd Ordinary Shares's free cash flow?

Basel Medical Group Ltd Ordinary Shares (BMGL) reported negative free cash flow of $4.4M in 2024, indicating capital requirements exceeded cash from operations.

What is Basel Medical Group Ltd Ordinary Shares's capital expenditure (CapEx)?

Basel Medical Group Ltd Ordinary Shares (BMGL) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.